HOME >> MEDICINE >> NEWS
ARVO keynote speakers to explore worldwide vision research collaborations

. Rao received his basic medical education in Guntur, Andhra Pradesh, and completed his postgraduate training in ophthalmology at the All India Institute for Medical Sciences, New Delhi. He came to the United States in 1972, where he trained at Tufts University School of Medicine in Boston, and later at the University of Rochester School of Medicine. He continued to practice and teach in Rochester until his return to India in 1986. His areas of specialization include diseases of the cornea, eye banking and corneal transplantation, and community eye health. He has been actively involved in the development of numerous collaborations between the United States and India and, in his role as President of the IABP, he leads the global initiative to eliminate avoidable blindness by the year 2020.


'"/>

Contact: Elinore Tibbetts
etibbetts@arvo.org
240-221-2923
Association for Research in Vision and Ophthalmology
19-Apr-2006


Page: 1 2

Related medicine news :

1. Dobbs to give plenary keynote at Drug Information Association conference in Philadelphia, Sept. 26
2. Nobel Laureate keynote speaker at conference on nanomedicine, geriatric care, brain injury
3. UK aging expert signs on as keynote speaker for GSAs annual meeting
4. The Gerontolgogical Society of America taps Aetnas Rowe as annual meeting keynote speaker
5. SNMs 54th Annual Meeting speakers address state of molecular imaging/nuclear medicine technologies
6. Brain processing of speech sounds is different in some southern English speakers
7. New health information resource from Tufts for Asian-language speakers
8. Drug-eluting stent controversy explored in the American Heart Hospital Journal
9. ESA satellite guides polar explorers across disintegrating sea ice
10. ISHLT membership explores expansion of computer modeling system for organ allocation
11. Scientists and polar explorers brave the elements in support of CryoSat-2

Post Your Comments:
(Date:11/26/2014)... 2014 GI for Life announced today, ... in prices of their popular nutritional supplements: ColoVite ... . Discounts of 40% will be offered for ... Life’s proprietary ColoVite supplement is a scientifically formulated vitamin ... health. One easy-to-take colon vitamin with ALL the nutrients ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Call 866-997-4948 ... requirements or email the details on sales(at)researchmoz(dot)us , ... and drug discovery market 2014" with deep study of ... the result of high blood sugar. The global glucose ... linked to the growing number of diabetics in the ...
(Date:11/26/2014)... News Facts , Lexmark’s Perceptive ... 2014 in Chicago. The company will demonstrate solutions ... photos, videos and documents found throughout the healthcare ... more about these innovative medical content management solutions ... – that enable more informed clinical decisions, promote ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
(Date:11/26/2014)... need to take an active role in protecting their ... must make sure sports-playing teens have the right protective ... the American Migraine Foundation and a professor of medicine ... Ariz. in an American Migraine Foundation, said in a ... teens sports needs to have appropriate training. Teen sports ...
Breaking Medicine News(10 mins):Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Parents Need to Take Lead on Teen Concussion Prevention 2
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China , Nov. 26, 2014 / -- China Nepstar Chain ... "Company"), a leading retail drugstore chain in ... operated stores, today announced the appointment of Ms. ... Officer, effective immediately. Ms.Zhang has over ... joined Nepstar in March 1999. Prior to Ms. Zhang,s ...
(Date:11/24/2014)... -- Juno Therapeutics today announced that the FDA ... JCAR015 chimeric antigen receptor product candidate.  The designation ... B-cell acute lymphoblastic leukemia and was filed by ... where Phase 1 clinical trials are currently underway. ... news for patients who may benefit from the ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
Cached News: